prime medicine(PRME) - 2024 Q3 - Quarterly Results

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates -- Presented initial in vivo data for universal liver-targeted LNP and Wilson's Disease program at ESGCT; initiated IND-enabling activities for Wilson's Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 -- -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than$3.5 billion in milestone pay ...